Q2 2026 saw revenue rise 6.5% organically to $1.16B, with non-GAAP EPS up 10% to $1.31. Sequencing instruments led growth, while Greater China declined. FY26 guidance projects continued mid-single-digit organic growth and stable margins.Original document: Illumina, Inc. [ILMN] Slides Release — Jul…
Q2 2026 saw revenue rise 6.5% organically to $1.16B, with non-GAAP EPS up 10% to $1.31. Sequencing instruments led growth, while Greater China declined. FY26 guidance projects continued mid-single-digit organic growth and stable margins.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
